Pa­tient death spurs tri­al halt for Ma­gen­ta Ther­a­peu­tics

Ma­gen­ta Ther­a­peu­tics is paus­ing an ear­ly-stage clin­i­cal tri­al af­ter a pa­tient died. The death was deemed to be pos­si­bly re­lat­ed to its drug, MG­TA-117.

The biotech said the pause of the Phase I/II tri­al is vol­un­tary and gives it time to re­view all avail­able da­ta be­fore de­cid­ing what to do next. It’s al­so re­port­ed the known in­for­ma­tion to the FDA.

The dose-es­ca­la­tion tri­al was de­signed to test whether MG­TA-117, an an­ti­body-drug con­ju­gate, could serve as a more tar­get­ed al­ter­na­tive to high-in­ten­si­ty chemother­a­py as a con­di­tion­ing agent for can­cer pa­tients who are set to re­ceive a stem cell trans­plant. It re­cruit­ed pa­tients with re­lapsed/re­frac­to­ry acute myeloid leukemia and myelodys­plas­tic syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER